spacer
home > ict > autumn 2009 > solutions central
PUBLICATIONS
International Clinical Trials

Solutions Central

 

TODAY’S CHALLENGE

Over the past 20 years or so, the pharmaceutical service industry has witnessed dramatic changes in the complexity of the compounds being developed and investigated. Along with this complexity came the rationalisation of resources and core competencies in the large and not-solarge pharmas and biotechs, increasing the need for outsourcing the development of speciality assays and biomarkers. With the rapid evolution of molecular biology, immunology and genetic science, finding a competent laboratory with the qualifications and experience to meet the R&D objectives for preclinical and clinical development is a challenge for most drug developers. During the current period of intense change, demand is also increasing due to mergers and acquisitions and the subsequent rationalisation of staffing to meet the economic objectives of the M&A. Conservation of cash by others is resulting in staff reductions and more and more outsourcing to speciality houses that provide the required expertise.

Once the decision to outsource has been taken, a number of additional steps must be considered. A general process would be to identify the types of assays needed (safety assessments, biomarkers, esoteric assays), build a relationship with an appropriate central laboratory that has the capacity to manage your R&D project, negotiate the project parameters so that communication and expectations are clear, and maintain clear communication channels throughout the project to help ensure success in its development.

TODAY’S ENVIRONMENT

Biomarkers and speciality or esoteric assays are today playing an increasingly important role across the clinical development spectrum. From large molecule pharmacokinetic assays and immunogenicity assays, to mutational analysis for subject selection to primary, secondary and exploratory endpoints, biomarker and speciality assays have become critical components in every phase of development.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Fraser R Day is a Canadian pharmacist with more than 40 years’ experience in the pharmaceutical, preclinical and clinical trial industries. He has held various strategic sales, marketing and business development positions in all three sectors, including senior management responsibilities on an international scale. Currently Fraser holds the position of Vice- President, Business Development, at CIRION Clinical Trial Services, a Contract R&D and central laboratory in Canada.
spacer
Fraser R Day
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Labguru integrates free video conferencing & documenting tool to support remote lab collaboration during COVID-19

2 April 2020, Cambridge MA – Electronic laboratory notebook (ELN) pioneer, BioData, today announces its support for the global science community with the introduction of a new video conferencing service in its leading Labguru ELN platform, free of charge for all customers.
More info >>

White Papers

galenIQ - The smart excipient

BENEO GmbH

galenIQ combines a multitude of outstanding characteristics and is suitable for a wide range of pharmaceutical applications. galenIQ can be used as more than just a bulk excipient. It also serves as an anti-caking agent, anti-humectant agent, stabilizer or oral care and taste agent to mention just a few additional functions.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement